人工智能引导的组织分析联合免疫浸润评估预测III期结肠癌预后:PETACC08研究
该研究开发了基于CD3和CD8染色切片的软件,自动量化肿瘤核心和浸润边缘的淋巴细胞密度与面积,并用LASSO算法(DGMate)检测与患者结局相关的数字参数。在1018例患者数据集中,高浸润边缘间质面积和高DGMate与较差的無復發生存期相关,而CD3+肿瘤核心、CD3+浸润边缘和CD8+肿瘤核心密度较高与较长的無復發生存期显著相关。联合浸润边缘间质面积、DGMate和CD3的DGMuneS在预测预后方面优于Immunoscore(C-index=0.601 vs 0.578,p=0.04),且经Cox多变量分析独立于患者结局。
要点
- 高浸润边缘间质面积和高DGMate与较差的無復發生存期独立相关。
- CD3+肿瘤核心、CD3+浸润边缘和CD8+肿瘤核心密度较高与较长的無復發生存期显著相关。
- DGMuneS联合模型预测预后优于Immunoscore,并可识别复发风险低于10%和50%的患者组。
核心结论
- 人工智能辅助病理分析可改善III期结肠癌患者的预后评估。
研究设计与样本
- 研究基于PETACC08研究数据集,共纳入1018例患者,开发软件在CD3和CD8染色切片上自动检测结肠肿瘤、健康黏膜、间质和免疫细胞。
- 使用LASSO算法DGMate检测肿瘤细胞中与患者结局相关的数字参数。
主要发现
- 高浸润边缘间质面积与较差的無復發生存期相关(HR 5.65;95% CI 2.34至13.67;p<0.0001)。
- 高DGMate与较差的無復發生存期相关(HR 2.72;95% CI 1.92至3.85;p<0.001)。
- CD3+肿瘤核心、CD3+浸润边缘和CD8+肿瘤核心密度较高与较长的無復發生存期显著相关。
- CD3+肿瘤核心的预后价值与经典CD3/CD8 Immunoscore相似(p=0.44)。
- DGMuneS(联合浸润边缘间质面积、DGMate和CD3)预测预后优于Immunoscore(C-index=0.601 vs 0.578,p=0.04),且经Cox多变量分析独立于患者结局。
关键数值与推荐
- 高浸润边缘间质面积:HR 5.65;95% CI 2.34至13.67;p<0.0001。
- 高DGMate:HR 2.72;95% CI 1.92至3.85;p<0.001。
- DGMuneS与Immunoscore的C-index比较:0.601 vs 0.578,p=0.04。
- CD3+肿瘤核心与经典CD3/CD8 Immunoscore预后价值比较:p=0.44。
临床怎么用
- 人工智能工具可辅助病理学家更准确地定义III期结肠癌患者的预后。
- DGMuneS模型可用于识别复发风险低于10%和50%的患者组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Diagnostic tests, such as Immunoscore, predict prognosis in patients with colon cancer. However, additional prognostic markers could be detected on pathological slides using artificial intelligence tools. DESIGN: We have developed a software to detect colon tumour, healthy mucosa, stroma and immune cells on CD3 and CD8 stained slides. The lymphocyte density and surface area were quantified automatically in the tumour core (TC) and invasive margin (IM). Using a LASSO algorithm, DGMate (DiGital tuMor pArameTErs), we detected digital parameters within the tumour cells related to patient outcomes. RESULTS: Within the dataset of 1018 patients, we observed that a poorer relapse-free survival (RFS) was associated with high IM stromal area (HR 5.65; 95% CI 2.34 to 13.67; p<0.0001) and high DGMate (HR 2.72; 95% CI 1.92 to 3.85; p<0.001). Higher CD3+ TC, CD3+ IM and CD8+ TC densities were significantly associated with a longer RFS. Analysis of variance showed that CD3+ TC yielded a similar prognostic value to the classical CD3/CD8 Immunoscore (p=0.44). A combination of the IM stromal area, DGMate and CD3, designated 'DGMuneS', outperformed Immunoscore when used in estimating patients' prognosis (C-index=0.601 vs 0.578, p=0.04) and was independently associated with patient outcomes following Cox multivariate analysis. A predictive nomogram based on DGMuneS and clinical variables identified a group of patients with less than 10% relapse risk and another group with a 50% relapse risk. CONCLUSION: These findings suggest that artificial intelligence can potentially improve patient care by assisting pathologists in better defining stage III colon cancer patients' prognosis.
引用
- Reichling C, Taieb J, Derangere V, et al. Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study. Gut. 2019. PMID: 31780575. doi:10.1136/gutjnl-2019-319292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。